REFERENCES
- Delfraissy JF, Flandre P, Delaugerre C, et al. MONARK trial (MONotherapy AntiRetroviral Kaletra): lopinavir/ritonavir (LPV/r) monotherapy or plus zidovudine and lamivu-dine in antiretroviral-naive HIV infected patients. AIDS. 2008;22:385–393.
- Campo RE, Lalanne R, Tanner TJ, et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppres-sion with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005;19:447–449.
- Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleo-sides for maintenance therapy of HIV: 96-week results. J Acquir Immune Defic Syndr 2009;51:142–157.
- Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral sup-pression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005;40:280–287.
- Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clini-cal Trials Group (AACTG). AIDS Care. 2000;12:255–266.
- Badri M, Ehrlich R, Pulerwitz T, et al. Tuberculosis should not be considered an AIDS-defining illness in areas with a high tuberculosis prevalence. Int J Tuberc Lung Dis. 2002 ;6(3):231–237.
- Sprinz E, Bay MB, Lazzaretti RK, et al. Lopinavir/ritonavir monotherapy as maintenance treatment in HIV-infected individuals with virological suppression: results from a pilot study in Brazil. HIV Med. 2008;9:270–276.
- Cameron W, da Silva BA, Arribas J, et al. A 96-week com-parison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combi-nation therapy. J Infect Dis. 2008;198:234–240.
- Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009; 23(3):279–291.
- Vergara TR, Estrela RC, Suarez-Kurtz G, et al. Limited penetra-tion of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil. Ther Drug Monitor 2006;28:175–179.
- Vernazza P, Daneel S, Schiffer V, et al. The role of com-partment penetration in PI-monotherapy: the Atazanayir-Ritonayir Monomaintenance (ATARITMO) Trial. AIDS. 2007;21:1309–1315.
- Sahali S, Chaix M, Delfraissy JF, et al. Ritonavir-boosted protase inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev. 2008;10: 4–14.
- Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639): 646–655.